Insight Molecular Diagnostics (IMDX) Total Current Liabilities (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Total Current Liabilities data on file, last reported at $12.0 million in Q1 2026.

• Quarterly Total Current Liabilities rose 23.98% year-over-year to $12.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.0 million (up 23.98% YoY) and the FY2025 annual result came in at $12.1 million, up 65.98% from the prior year.
• Total Current Liabilities retreated to $12.0 million in Q1 2026 per IMDX's latest filing, from $12.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $14.2 million in Q2 2022, with the low at $6.7 million in Q2 2025.
• Average Total Current Liabilities over 5 years is $9.7 million, with a median of $9.1 million recorded in 2024.
• Year-over-year, Total Current Liabilities tumbled 45.83% in 2023 and jumped 65.98% in 2025.
• Insight Molecular Diagnostics' Total Current Liabilities stood at $12.1 million in 2022, then tumbled by 40.57% to $7.2 million in 2023, then advanced by 1.13% to $7.3 million in 2024, then jumped by 65.98% to $12.1 million in 2025, then fell by 0.58% to $12.0 million in 2026.
• Business Quant data shows IMDX's Total Current Liabilities at $12.0 million in Q1 2026, $12.1 million in Q4 2025, and $7.7 million in Q3 2025.